Table 1.
Descriptive characteristics of the GISELA subjects at baseline a.
| Parameter | Total (n = 399) | Women (n = 278) | Men (n = 121) | |||
|---|---|---|---|---|---|---|
| Median | Q25, Q75 | Median | Q25, Q75 | Median | Q25, Q75 | |
| Age (years) | 66 | 62, 70 | 67 | 62, 71 | 66 | 63, 70 |
| Body mass index (kg/m2) | 26 | 24, 29 | 26 | 24, 29 | 26 | 24, 28 |
| Fat-free mass (kg) | 42 | 38, 52 | 39 | 38, 42 | 54 | 52, 58 |
| Fat mass (kg) | 27 | 22, 33 | 28 | 23, 35 | 23 | 19, 29 |
| Fat mass (%) | 39 | 33, 44 | 42 | 38, 46 | 30 | 27, 33 |
| Plasma vitamin C (µmol/L) | 74 | 64, 85 | 77 | 67, 88 | 68 | 60, 76 |
| Plasma α-tocopherol (µmol/L) | 35 | 29, 42 | 36 | 30, 42 | 32 | 27, 39 |
| Serum cholesterol (mmol/L) | 5.8 | 5.2, 6.4 | 5.9 | 5.3, 6.5 | 5.6 | 4.7, 6.2 |
| Energy intake (MJ/d) | 8.5 | 7.1, 10 | 8.1 | 6.8, 9.6 | 9.9 | 8.0, 12 |
| Vitamin C intake (mg/d) | 117 | 84, 152 | 117 | 84, 156 | 117 | 83, 138 |
| Vitamin E intake (mg/d) b | 9.9 | 7.5, 14 | 9.8 | 7.4, 14 | 10 | 8.0, 13 |
| PUFA intake (g/d) | 10 | 7.7, 13 | 9.6 | 7.1, 13 | 11 | 8.4, 14 |
| Physical activity index | 1.7 | 1.6, 1.8 | 1.7 | 1.6, 1.8 | 1.7 | 1.6, 1.8 |
| n | % | n | % | n | % | |
| Female sex | 278 | 70 | ||||
| Vitamin C supplement users | 112 | 28 | 81 | 29 | 31 | 26 |
| Vitamin E supplement users | 107 | 27 | 81 | 29 | 26 | 22 |
| Multivitamin supplement users | 104 | 26 | 79 | 28 | 25 | 21 |
| Current/past smokers | 178 | 45 | 86 | 31 | 92 | 76 |
| Users of lipid-modifying drugs | 63 | 16 | 48 | 17 | 15 | 12 |
| Disease diagnosis c | 236 | 59 | 180 | 65 | 56 | 46 |
PUFA, polyunsaturated fatty acids. a Data are presented as median and interquartile range indicated by 25% (Q25) and 75% (Q75) quartiles for continuous variables and absolute and relative frequencies for categorical variables, respectively; b Vitamin E intake is expressed in form of α-tocopherol equivalents; c This variable combined the information on reported diagnoses of gall bladder/pancreas/chronic liver/inflammatory bowel disease and dyslipidemia.